CD55 and non-small cell lung carcinoma: Additionally, 177Lu-anti-CD55 inhibited the survival of H358 cells (bronchioloalveolar carcinoma cells, a subtype of NSCLC), while unlabeled CD55-specific antibodies did not reduce viability (Fig. 6b).